Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Radiotherapy is one of the most successful cancer therapies. Here the effect of irradiation on antigen presentation by MHC class I molecules was studied. Cell surface expression of MHC class I molecules was increased for many days in a radiation dose-dependent manner as a consequence of three responses. Initially, enhanced degradation of existing proteins occurred which resulted in an increased intracellular peptide pool. Subsequently, enhanced translation due to activation of the mammalian target of rapamycin pathway resulted in increased peptide production, antigen presentation, as well as cytotoxic T lymphocyte recognition of irradiated cells. In addition, novel proteins were made in response to gamma-irradiation, resulting in new peptides presented by MHC class I molecules, which were recognized by cytotoxic T cells. We show that immunotherapy is successful in eradicating a murine colon adenocarcinoma only when preceded by radiotherapy of the tumor tissue. Our findings indicate that directed radiotherapy can improve the efficacy of tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“irradiation can also increase tumor antigenicity through enriching the pool of antigenic peptides”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Reits et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“folding the HLA-A1 heavy chain with peptides CGI-51(206–215), MSH6(469–478), and F-box protein Fbl7(335–362) and human β2m as described (51).”
BackgroundDNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Rapid degradation of a large fraction of newly synthesized proteins by proteasomes
Schubert, U., Antón, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., & Bennink, J. R. (2000) · Nature · doi:10.1038/35008096 · Cited by 1,536
Error-Tolerant Identification of Peptides in Sequence Databases by Peptide Sequence Tags
Mann, M., & Wilm, M. (1994) · Analytical Chemistry · doi:10.1021/ac00096a002 · Cited by 1,468
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
Demaria, S., Ng, B., Devitt, M. L., Babb, J. S., Kawashima, N., Liebes, L., & Formenti, S. C. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.012 · Cited by 1,388
Fingar, D. C., & Blenis, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207542 · Cited by 1,247
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 3×
“This is probably not due only to up-regulation of MHC class I expression because mTOR activation will have more general eff ects on protein expression including up-regulation of Fas, ICAM-1 (38), and interferon expression (33, 34).”
Background
Research works printed but not linked: 5
- 2000, Oncology (Huntingt), 14, 741
- 1988, Nippon Igaku Hoshasen Gakkai Zasshi., 48, 1572
- 2000, Anticancer Res., 20, 3375
- 2002, Cancer Res., 62, 1462
- 1991, Cancer Res., 51, 3657
Cited by
Items 701–800 of 1,000
Mackay, L. K., Long, H. M., Brooks, J. M., Taylor, G. S., Leung, C. S. K., Chen, A., Wang, F., & Rickinson, A. B. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000699 · Cited by 36
Accolla, R. S., & Tosi, G. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-154 · Cited by 38
Dovedi, S. J., Adlard, A. L., Ota, Y., Murata, M., Sugaru, E., Koga‐Yamakawa, E., Eguchi, K., Hirose, Y., Yamamoto, S., Umehara, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7928 · Cited by 36
Immunotherapy and radiation in glioblastoma
Sahebjam, S., Sharabi, A. B., Lim, M. K., Kesarwani, P., & Chinnaiyan, P. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2413-0 · Cited by 36
Bockel, S., Durand, B., & Deutsch, É. (2018) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2018.07.136 · Cited by 36
Low‐dose radiation therapy mobilizes antitumor immunity: New findings and future perspectives
Zhou, L., Liu, Y., Wu, Y., Yang, X., Kong, F., Lü, Y., & Xue, J. (2023) · International Journal of Cancer · doi:10.1002/ijc.34801 · Cited by 35
Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
Rajani, K. R., Carlstrom, L. P., Parney, I. F., Johnson, A. J., Warrington, A. E., & Burns, T. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00656 · Cited by 35
Wu, L., Tang, Q., Yin, X., Yan, D., Tang, M., Xin, J., Pan, Q., Ma, C., & Yan, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00267 · Cited by 36
Current and future immunotherapy approaches in ovarian cancer
Demircan, N. C., Boussios, S., Taşçı, T., & Öztürk, M. A. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-4499 · Cited by 35
Domankevich, V., Efrati, M., Schmidt, M. T., Glikson, E., Mansour, F., Shai, A., Cohen, A., Zilberstein, Y., Flaisher, E., Galalae, R. M., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00990 · Cited by 35
Khalifa, J., Mazières, J., Gomez‐Roca, C., Ayyoub, M., & Moyal, E. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.662236 · Cited by 35
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
Mielgo-Rubio, X., Montemuiño, S., Jiménez, U., Luna, J., Cardeña-Gutiérrez, A., Mezquita, L., Martín, M., & Couñago, F. (2021) · Cancers · doi:10.3390/cancers13194811 · Cited by 35
Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases
He, K., Barsoumian, H. B., Bertolet, G., Verma, V., Leuschner, C., Koay, E. J., Ludmir, E. B., Hsu, E. Y., Pisipati, E., Voss, T. A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.812210 · Cited by 35
The Evolving Interplay of SBRT and the Immune System, along with Future Directions in the Field
Miljanic, M., Montalvo, S. K., Aliru, M. L., Song, T., Leon-Camarena, M., Innella, K., Vujovic, D., Komaki, R. R., & Iyengar, P. (2022) · Cancers · doi:10.3390/cancers14184530 · Cited by 35
Liu, Y., Crowe, W. N., Wang, L., Petty, W. J., Habib, A. A., & Zhao, D. (2022) · Nano Research · doi:10.1007/s12274-022-5205-6 · Cited by 35
Immunotherapy eradicates metastases with reversible defects in MHC class I expression
Garrido, C., Romero, I., Berruguilla, E., Cancela, B., Algarra, I., Collado, A., Garcia-Lora, A. M., & Garrido, F. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1027-1 · Cited by 35
Garnett‐Benson, C., Hodge, J. W., & Gameiro, S. R. (2014) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.002 · Cited by 35
Self-citationGuo, C., Yi, H., Yu, X., Zuo, D., Qian, J., Yang, G., Foster, B. A., Subjeck, J. R., Sun, X., Mikkelsen, R. B., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0164 · Cited by 36
Walker, J. M., Rolig, A. S., Charych, D. H., Hoch, U., Kasiewicz, M. J., Rose, D. C., McNamara, M. J., Hilgart-Martiszus, I., & Redmond, W. L. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000464 · Cited by 35
Yu, J., Li, M., Ren, B., Cheng, L., Wang, X., Ma, Z., Yong, W. P., Chen, X., Wang, L., & Goh, B. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1261575 · Cited by 34
Pannunzio, S., Bello, A. D., Occhipinti, D., Scala, A., Messina, G., Valente, G., Quirino, M., Salvatore, M. D., Tortora, G., & Cassano, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1288695 · Cited by 34
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors
Wu, Y., Yi, M., Niu, M., Zhou, B., Mei, Q., & Wu, K. (2024) · 癌症:英文版 · doi:10.1002/cac2.12576 · Cited by 34
Rekers, N. H., Troost, E. G. C., Zegers, C. M. L., Germeraad, W. T. V., Dubois, L. J., & Lambin, P. (2014) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2014.06.012 · Cited by 34
Kroon, P., Gadiot, J., Peeters, M. J. W., Gasparini, A., Deken, M. A., Yagita∥, H., Verheij, M., Borst, J. G., Blank, C. U., & Verbrugge, I. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1843-4 · Cited by 34
Franceschini, D., Franzese, C., Navarria, P., Ascolese, A. M., Rose, F. D., Vecchio, M. D., Santoro, A., & Scorsetti, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.003 · Cited by 34
Combinations of radiotherapy with immunotherapy in cervical cancer
Yang, X., Ren, H., & Fu, J. (2022) · Journal of Cancer · doi:10.7150/jca.65074 · Cited by 34
He, J., Yan, Y., Zhang, J., Wei, Z., Li, H., & Xing, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298683 · Cited by 34
Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
Hodge, J. W., Kwilas, A. R., Ardiani, A., & Gameiro, S. R. (2013) · OncoImmunology · doi:10.4161/onci.26937 · Cited by 34
Self-citationContribution of mass spectrometry-based proteomics to immunology
Hillen, N., & Stevanović, S. (2006) · Expert Review of Proteomics · doi:10.1586/14789450.3.6.653 · Cited by 34
Immuno-oncology: Allying forces of radio- and immuno-therapy to enhance cancer cell killing
Bernier, J. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.001 · Cited by 34
Rosati, L. M., Kumar, R., & Herman, J. M. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.02.005 · Cited by 34
Morisada, M. V., Moore, E. C., Hodge, R., Friedman, J., Cash, H. A., Hodge, J. W., Mitchell, J. B., & Allen, C. T. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.06.005 · Cited by 34
Self-citationCombined use of NK cells and radiotherapy in the treatment of solid tumors
Wang, Z., Ling, S., Cao, Y., Shao, C., & Sun, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1306534 · Cited by 33
Inorganic Nanoparticle Functionalization Strategies in Immunotherapeutic Applications
Mao, W., & Yoo, H. S. (2024) · Biomaterials Research · doi:10.34133/bmr.0086 · Cited by 33
Reddy, J. P., Sherry, A. D., Fellman, B. M., Liu, S., Bathala, T. K., Haymaker, C., Cohen, L. G., Smith, B. D., Ramirez, D., Shaitelman, S. F., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.10.030 · Cited by 33
Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Puri, S., Saltos, A. N., Perez, B. A., Le, X., & Gray, J. E. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0882-3 · Cited by 33
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer
Staniszewska, M., Iking, J., Lückerath, K., Hadaschik, B. A., Herrmann, K., Ferdinandus, J., & Fendler, W. P. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.03.009 · Cited by 33
Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy
Pietryga, I. F., Miyauchi, S., Kim, S. S., Sanders, P. D., Sumner, W., Zhang, L., Mundt, A. J., Califano, J. A., & Sharabi, A. B. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.08.037 · Cited by 33
Tumor and immune remodeling following radiotherapy in human renal cell carcinoma
Chow, J. L., Khan, A., Gaudieri, M., Wasik, B. J., Conway, A. N., Soh, K. T., Repasky, E. A., Schwaab, T., Wallace, P. K., Abrams, S. I., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006392 · Cited by 33
Modulation of CTLA-4 and GITR for Cancer Immunotherapy
Avogadri, F., Yuan, J. D., Yang, A. S., Schaer, D., & Wolchok, J. D. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_49 · Cited by 33
Spary, L. K., Al‐Taei, S., Salimu, J., Cook, A. D., Ager, A., Watson, H. A., Clayton, A., Staffurth, J. N., Mason, M. D., & Tabi, Z. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302736 · Cited by 33
Novel radiosensitizing anticancer therapeutics.
Linkous, A. G., & Yazlovitskaya, E. M. (2012) · PubMed · Cited by 33
Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation
Eckert, F., Gaipl, U. S., Niedermann, G., Hettich, M., Schilbach, K., Huber, S. M., & Zips, D. (2017) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2016.12.006 · Cited by 33
Cancer treatment and the KIR–HLA system: an overview
Leone, P., Re, V. D., Vacca, A., Dammacco, F., & Racanelli, V. (2017) · Clinical and Experimental Medicine · doi:10.1007/s10238-017-0455-4 · Cited by 33
Koenig, J. L., Shi, S., Sborov, K. D., Gensheimer, M. F., Li, G., Nagpal, S., Chang, S. D., Gibbs, I. C., Soltys, S. G., & Pollom, E. L. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.03.110 · Cited by 33
Tanigawa, K., & Redmond, W. L. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2452654 · Cited by 32
The Curative Outcome of Radioimmunotherapy in a Mouse Breast Cancer Model Relies on mTOR Signaling
Verbrugge, I., Gasparini, A., Haynes, N. M., Hagekyriakou, J., Gallí, M., Stewart, T. J., Abrams, S. I., Yagita∥, H., Verheij, M., Johnstone, R. W., et al. (2014) · Radiation Research · doi:10.1667/rr13511.1 · Cited by 32
Self-citationPunnanitinont, A., Kannisto, E. D., Matsuzaki, J., Odunsi, K. O., Yendamuri, S., Singh, A. K., & Patnaik, S. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072573 · Cited by 32
Xia, W.-Y., Feng, W., Zhang, C., Shen, Y., Zhang, Q., Yu, W. J., Cai, X., & Fu, X. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-827 · Cited by 32
Boopathi, E., & Thangavel, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810126 · Cited by 32
Sheng, J., Li, H., Yu, X., Yu, S., Chen, K., Pan, G., Xie, M., Li, N., Zhou, Z., & Fan, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14171 · Cited by 33
The SPPL3-defined glycosphingolipid repertoire orchestrates HLA class I-mediated immune responses
Jongsma, M. L. M., de Waard, A. A., Raaben, M., Zhang, T., Cabukusta, B., Platzer, R., Blomen, V. A., Xagara, A., Verkerk, T., Bliss, S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.016 · Cited by 32
Self-citationHerskind, C., Wenz, F. K., & Giordano, F. A. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00147 · Cited by 32
The 100 top-cited studies in cancer immunotherapy
Zhang, Y., Quan, L., & Du, L. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1623234 · Cited by 32
Laggner, U., Lopez, J. S., Perera, G., Warbey, V. S., Sita-Lumsden, A. R., O'Doherty, M. J., Hayday, A., Harries, M., & Nestle, F. O. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.01.008 · Cited by 32
Increased Seroreactivity to Glioma-Expressed Antigen 2 in Brain Tumor Patients under Radiation
Heisel, S., Ketter, R., Keller, A., Klein, V., Pallasch, C. P., Lenhof, H., & Meese, E. U. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002164 · Cited by 31
Radiotherapy and immune checkpoint blockades: a snapshot in 2016
Koo, T., & Kim, I. A. (2016) · Radiation Oncology Journal · doi:10.3857/roj.2016.02033 · Cited by 31
Immunological effect of local ablation combined with immunotherapy on solid malignancies
Takahashi, Y., Matsutani, N., Nakayama, T., Dejima, H., Uehara, H., & Kawamura, M. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0216-5 · Cited by 32
Gao, S., Jung, J., Lin, S., Jang, A.-Y., Zhi, Y., Ahn, K. B., Ji, H.-J., Lim, J. H., Guo, H., Choy, H. E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60396-6 · Cited by 31
Chen, J., Chen, C., Zhan, Y., Zhou, L., Chen, J., Cai, Q., Wu, Y., Sui, Z., Zeng, C., Wei, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4521 · Cited by 31
Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies
Ukleja, J., Kusaka, E., & Miyamoto, D. T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.663852 · Cited by 31
Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside
Meattini, I., Livi, L., Lorito, N., Becherini, C., Bacci, M., Visani, L., Fozza, A., Belgioia, L., Loi, M., Mangoni, M., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102417 · Cited by 31
Tailor, A., Estéphan, H., Parker, R. S., Woodhouse, I. B., Abdulghani, M., Nicastri, A., Jones, K. I., Salatino, S., Muschel, R. J., Humphrey, T. C., et al. (2022) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2022.100410 · Cited by 31
Wang, J., Li, J., Wu, Y., Xu, X., Qian, X., Lei, Y., Liu, H., Zhang, Z., & Li, Y. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03227 · Cited by 31
Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy
Morel, D., Robert, C., Paragios, N., Grégoire, V., & Deutsch, É. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3632 · Cited by 31
Sin, J., Kim, J., Bae, S. H., Lee, I. H., Park, J. S., & Ryoo, H. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.32 · Cited by 31
Tatum, A. M., Mylin, L. M., Bender, S. J., Fischer, M. A., Vigliotti, B. A., Tevethia, M. J., Tevethia, S. S., & Schell, T. D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.4406 · Cited by 31
Radiobiological aspects of intraoperative tumour-bed irradiation with low-energy X-rays (LEX-IORT)
Herskind, C., & Wenz, F. K. (2014) · Translational Cancer Research · doi:10.21037/2090 · Cited by 31
Sato, H., Suzuki, Y., Yoshimoto, Y., Noda, S., Murata, K., Takakusagi, Y., Okazaki, A., Sekihara, T., & Nakano, T. (2017) · Clinical Case Reports · doi:10.1002/ccr3.758 · Cited by 31
Candidate immune biomarkers for radioimmunotherapy
Lévy, A., Nigro, G., Sansonetti, P. J., & Deutsch, É. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.006 · Cited by 31
Combining Heavy-Ion Therapy with Immunotherapy: An Update on Recent Developments
Helm, A., Ebner, D. K., Tinganelli, W., Simoniello, P., Bisio, A., Marchesano, V., Durante, M., Yamada, S., & Shimokawa, T. (2018) · International Journal of Particle Therapy · doi:10.14338/ijpt-18-00024.1 · Cited by 31
Radiotherapy as a New Player in Immuno-Oncology
Wang, S.-J., & Haffty, B. G. (2018) · Cancers · doi:10.3390/cancers10120515 · Cited by 31
Choi, J. S., Sansoni, E. R., Lovin, B. D., Lindquist, N. R., Phan, J., Mayo, L. L., Ferrarotto, R., & Su, S. Y. (2019) · Annals of Otology Rhinology & Laryngology · doi:10.1177/0003489419896602 · Cited by 31
Gamat, M., Jeon, D., Johnson, L. E., Moseman, J. E., Muralidhar, A., Potluri, H. K., Rastogi, I., Wargowski, E., Zahm, C. D., & McNeel, D. G. (2020) · Cancers · doi:10.3390/cancers12102831 · Cited by 32
Lin, Y.-T., Chen, Y., Luo, Z., & Wu, Y. (2024) · Nanoscale · doi:10.1039/d3nr05768b · Cited by 30
The Effects of Radiation Dose Heterogeneity on the Tumor Microenvironment and Anti-Tumor Immunity
Takashima, M. E., Berg, T. J., & Morris, Z. S. (2024) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2024.04.004 · Cited by 30
Breaking the shield of solid tumors: a combined approach for enhanced efficacy of CAR-T cells
Khaliulin, M., Valiullina, A., Petukhov, A., Yuan, Y., Spada, S., & Bulatov, E. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03817-z · Cited by 30
Hlavata, Z., Solinas, C., Silva, P. D., Porcu, M., Saba, L., Willard-Gallo, K. E., & Scartozzi, M. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0556-3 · Cited by 30
Botticella, A., Mezquita, L., Pechoux, C. L., & Planchard, D. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466619885530 · Cited by 30
Immune checkpoint inhibition in patients treated with stereotactic radiation for brain metastases
Kowalski, E. S., Remick, J. S., Sun, K., Alexander, G. S., Khairnar, R. R., Morse, E., Cherng, H. R. R., Berg, L. J., Poirier, Y. P., Lamichhane, N., et al. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01644-x · Cited by 30
Critical DNA damaging pathways in tumorigenesis
Kloeber, J. A., & Lou, Z. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.012 · Cited by 30
Shirasawa, M., Yoshida, T., Imabayashi, T., Okuma, K., Matsumoto, Y., Masuda, K., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.013 · Cited by 30
Sodji, Q. H., Nambiar, D. K., Viswanathan, V., von Eyben, R., Colburg, D. R. C., Binkley, M. S., Li, C. G., Olcina, M. M., Chang, D. T., Le, Q., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0069 · Cited by 30
Challenges and exploration for immunotherapies targeting cold colorectal cancer
Li, D., Tang, Y., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i1.55 · Cited by 30
Wattenberg, M. M., Kwilas, A. R., Gameiro, S. R., Dicker, A. P., & Hodge, J. W. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.79 · Cited by 30
Self-citationImmunotherapy for neuro-oncology: the critical rationale for combinatorial therapy
Reardon, D. A., Gilbert, M. R., Wick, W., & Liau, L. M. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov178 · Cited by 31
The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors
Luksik, A. S., Maxwell, R., Garzón-Muvdi, T., & Lim, M. K. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0513-3 · Cited by 30
Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide
Appelbe, O. K., Moynihan, K. D., Flor, A. C., Rymut, N., Irvine, D. J., & Kron, S. J. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.043 · Cited by 30
Efficacy of combined radiotherapy and anti‐programmed death 1 therapy in acral and mucosal melanoma
Kato, J., Hida, T., Someya, M., Sato, S., Sawada, M., Horimoto, K., Fujioka, M., Minowa, T., Matsui, Y., Tsuchiya, T., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.14805 · Cited by 30
Bloom, B. C., Augustyn, A., Pezzi, T. A., Menon, H., Mayo, L. L., Shah, S. J., Schwartz, D. L., Chmura, S. J., Johnson, F. M., Welsh, J. W., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00223 · Cited by 30
Nesseler, J. P., Lee, M.-H., Nguyen, C., Kalbasi, A. K., Sayre, J. W., Romero, T., Nickers, P., McBride, W. H., & Schaue, D. (2020) · Cancers · doi:10.3390/cancers12030714 · Cited by 30
Jiang, L., Zhao, X., Meng, X., & Yu, J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.045 · Cited by 30
In situ vaccination caused by diverse irradiation-driven cell death programs
Wang, Y., Li, Y., Yang, Y., Swift, M. L., Zhang, Z., Wu, S., Sun, Y., & Yang, K. (2024) · Theranostics · doi:10.7150/thno.86004 · Cited by 29
Zheng, Y., Li, C., Yu, B., Zhao, S., Li, J., Chen, X., & Li, H. (2021) · JTCVS Open · doi:10.1016/j.xjon.2021.11.003 · Cited by 29
Fluorescent tracking identifies key migratory dendritic cells in the lymph node after radiotherapy
Blair, T. C., Bambina, S., Kramer, G. F., Dowdell, A. K., Alice, A. F., Baird, J. R., Lund, A. W., Piening, B., Crittenden, M. R., & Gough, M. J. (2022) · Life Science Alliance · doi:10.26508/lsa.202101337 · Cited by 29
Radiotherapy-activated NBTXR3 nanoparticles modulate cancer cell immunogenicity and TCR repertoire
Darmon, A., Zhang, P., Marill, J., Anesary, N. M., SILVA, J. D., & Paris, S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02615-w · Cited by 29
Mechanistic rationales for combining immunotherapy with radiotherapy
Chi, A., & Nguyen, N. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125905 · Cited by 29
Immunothérapie et radiothérapie
Bockel, S., Antoni, D., Deutsch, É., & Mornex, F. (2017) · Cancer/Radiothérapie · doi:10.1016/j.canrad.2016.12.005 · Cited by 29
Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer
Kim, J. W., Shin, M. S., Kang, Y., Kang, I., & Petrylak, D. P. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.10.010 · Cited by 29
Vrankar, M., & Stanič, K. (2018) · Radiology and Oncology · doi:10.2478/raon-2018-0009 · Cited by 29
Metadata
- Authors
- Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., & Neefjes, J. J.
- Affiliations
- The Netherlands Cancer Institute (NL)
- 2Laboratory of Tumor Immunology and Biology
- National Institutes of Health (US)
- 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, and Centre for Medical Systems Biology, 2333 2A Leiden, Netherlands
- Leiden University Medical Center (NL)
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2006-04-24
- Volume
- 203
- Issue
- 5
- Pages
- 1259-1271
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3212727
- OpenAlex
- W2127733313
- Cited by
- 1,737
- References
- 53
- Citations by year
- 2026: 88 · 2025: 116 · 2024: 119 · 2023: 128 · 2022: 149 · 2021: 174 · 2020: 154 · 2019: 118 · 2018: 112 · 2017: 113 · 2016: 78 · 2015: 71 · 2014: 67 · 2013: 62 · 2012: 41
- FWCI
- 10.85
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- radiotherapy, gamma irradiation, MHC class I expression, antigen presentation, protein degradation, mTOR signaling, translation (biology), cytotoxic T lymphocytes, cancer immunotherapy, colon adenocarcinoma
- MeSH terms
- Adenocarcinoma, Animals, Colonic Neoplasms, Dose-Response Relationship, Radiation, Gamma Rays, Humans, Immunotherapy, Mice, Transgenic, Peptides, Protein Kinases, Radiotherapy, T-Lymphocytes, Cytotoxic, Protein Biosynthesis, HLA-A2 Antigen, Gene Expression Regulation, Neoplastic, Antigen Presentation, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.